We have located links that may give you full text access.
Journal Article
Meta-Analysis
Review
Modified Glasgow prognostic score might be a prognostic factor for hepatocellular carcinoma: a meta-analysis.
Panminerva Medica 2017 December
INTRODUCTION: Hepatocellular carcinoma (HCC) is the fifth-most common cancer. Recent studies have demonstrated that there was a relationship between modified Glasgow prognostic score (mGPS) and survival of HCC. However, the results were inconsistent.
EVIDENCE ACQUISITION: The following databases were searched for relevant articles published until June 2016: PubMed; EMBASE; Web of Science and the China National Knowledge Infrastructure. The strength of association between mGPS and OS of HCC was estimated by pooled HRs with corresponding 95% CIs.
EVIDENCE SYNTHESIS: Seven studies with 2047 HCC patients were included in this meta-analysis. The mGPS was an independent marker of poor prognosis in patients with HCC (HR=2.21; 95% CI: 1.73-2.82; I2=51%). In the subgroup analysis of study design, both prospective studies (HR=1.68; 95% CI: 1.35-2.11; I2=0%) and retrospective studies (HR=2.64; 95% CI: 1.92-3.62; I2=39%) with higher mGPS had shorter OS. The patients with resectable HCC and high mGPS also showed shorter OS (HR=2.33; 95% CI: 1.65-3.29; I2=63%). In the subgroup analysis by sample size, both large sample size studies (HR=2.56; 95% CI: 1.50-4.38; I2=72%) and small sample size studies (HR=2.00; 95% CI: 1.62-2.48; I2=0%) showed the same results.
CONCLUSIONS: In conclusion, this meta-analysis suggested that mGPS might be an independent prognostic factor for HCC.
EVIDENCE ACQUISITION: The following databases were searched for relevant articles published until June 2016: PubMed; EMBASE; Web of Science and the China National Knowledge Infrastructure. The strength of association between mGPS and OS of HCC was estimated by pooled HRs with corresponding 95% CIs.
EVIDENCE SYNTHESIS: Seven studies with 2047 HCC patients were included in this meta-analysis. The mGPS was an independent marker of poor prognosis in patients with HCC (HR=2.21; 95% CI: 1.73-2.82; I2=51%). In the subgroup analysis of study design, both prospective studies (HR=1.68; 95% CI: 1.35-2.11; I2=0%) and retrospective studies (HR=2.64; 95% CI: 1.92-3.62; I2=39%) with higher mGPS had shorter OS. The patients with resectable HCC and high mGPS also showed shorter OS (HR=2.33; 95% CI: 1.65-3.29; I2=63%). In the subgroup analysis by sample size, both large sample size studies (HR=2.56; 95% CI: 1.50-4.38; I2=72%) and small sample size studies (HR=2.00; 95% CI: 1.62-2.48; I2=0%) showed the same results.
CONCLUSIONS: In conclusion, this meta-analysis suggested that mGPS might be an independent prognostic factor for HCC.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app